Fig. 2 | Signal Transduction and Targeted Therapy

Fig. 2

From: Efficacy and safety of low-dose interleukin-2 in combination with methotrexate in patients with active rheumatoid arthritis: a randomized, double-blind, placebo-controlled phase 2 trial

Fig. 2The alternative text for this image may have been generated using AI.

Clinical responses to Ld-IL2 combined with MTX therapy. The data were presented in a per-protocol (PP) analysis set. The proportion of patients achieving an ACR20/50/70 response by at week 12 and 24 (a). The mean changes from baseline for CDAI and SDAI (b, c). The mean changes from baseline for pain, PtGA and PhGA of disease activity (d). Data in graphs were mean ± SE. *P < 0.05, with analyses with a logistic regression model or a covariance (ANCOVA) model at week 12 or 24. #P-value, presenting treatment differences across time points with a mixed model for repeated-measures analysis or Generalized Estimation Equations (GEE) method. ACR20/50/70 the American College of Rheumatology for 20%/50%/70% improvement, CDAI Clinical Disease Activity Index, SDAI Simplified Disease Activity Index, Ld-IL2 low-dose interleukin-2, MTX methotrexate, PtGA patient’s global assessment, PhGA physician’s global assessment

Back to article page